A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

ClinicalTrials.gov ID: NCT02815267

Public ClinicalTrials.gov record NCT02815267. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-04

Study identification

NCT ID: NCT02815267
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Vyne Therapeutics Inc.; Industry
Enrollment: 466 participants

Conditions and interventions

Conditions

Acne Vulgaris

Interventions

FMX-101, 4% minocycline foam Drug
Vehicle Foam Drug

Drug

Eligibility (public fields only)

Age range: 9 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2016
Primary completion: Oct 12, 2017
Completion: Oct 12, 2017
Last update posted: Jan 17, 2022

2016 – 2017

United States locations

U.S. sites: 30
U.S. states: 22
U.S. cities: 28

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35205	—
Not listed	Fremont	California	94538	—
Not listed	Fullerton	California	92835	—
Not listed	Shelton	Connecticut	06484	—
Not listed	Washington D.C.	District of Columbia	20037	—
Not listed	Boynton Beach	Florida	33437	—
Not listed	Miami	Florida	33015	—
Not listed	Miami	Florida	33174	—
Not listed	Miramar	Florida	33027	—
Not listed	Sanford	Florida	32771	—
Not listed	Savannah	Georgia	31406	—
Not listed	Oakbrook Terrace	Illinois	60181	—
Not listed	Evansville	Indiana	47713	—
Not listed	Metairie	Louisiana	70006	—
Not listed	Rockville	Maryland	20850	—
Not listed	Bay City	Michigan	48706	—
Not listed	Omaha	Nebraska	68114	—
Not listed	Las Vegas	Nevada	89117	—
Not listed	New York	New York	10012	—
Not listed	New York	New York	10075	—
Not listed	High Point	North Carolina	27262	—
Not listed	Columbus	Ohio	43213	—
Not listed	Gresham	Oregon	97030	—
Not listed	Johnston	Rhode Island	02919	—
Not listed	Murfreesboro	Tennessee	37130	—
Not listed	Dallas	Texas	75234	—
Not listed	Plano	Texas	75024	—
Not listed	San Antonio	Texas	78229	—
Not listed	West Jordan	Utah	84088	—
Not listed	Bridgeport	West Virginia	26330	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02815267, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 17, 2022 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02815267 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →